What are the major and minor criteria for diagnosing dermatomyositis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Criteria for Dermatomyositis

The 2017 EULAR/ACR classification criteria use a weighted probability-based scoring system rather than traditional "major and minor" criteria, with a score ≥5.5 (without biopsy) or ≥6.7 (with biopsy) indicating probable idiopathic inflammatory myopathy. 1, 2

Understanding the Modern Classification System

The traditional Bohan and Peter criteria with "major and minor" categories are now obsolete. 1 The current standard uses a data-driven probability model that assigns specific weighted scores to clinical, laboratory, and histopathologic features. 2

Key Weighted Variables in the Scoring System

Cutaneous manifestations receive the highest weights in the probability score: 1, 2

  • Heliotrope rash (violaceous periorbital erythema)
  • Gottron papules (erythematous papules over extensor surfaces of joints)
  • Gottron sign (erythematous macules over joints without papules)
  • V-sign (erythema over anterior chest in V-distribution)
  • Shawl sign (erythema over posterior shoulders and back)

Laboratory features contribute to the score: 2

  • Anti-Jo-1 antibody (assigned 3.9 points)
  • Elevated muscle enzymes including CK, aldolase, AST, ALT, LDH (assigned 1.3 points)
  • Other myositis-specific autoantibodies

Muscle-related findings are scored: 1, 2

  • Proximal muscle weakness (symmetric, upper and lower extremities)
  • Neck flexor weakness greater than extensor weakness
  • Dysphagia or esophageal dysmotility

Histopathologic features improve accuracy but are not mandatory: 1, 2

  • Perifascicular atrophy
  • Inflammation patterns
  • Muscle fiber changes

Classification Thresholds

The probability-based model defines certainty levels: 1, 2

  • Score ≥5.5 (without biopsy) or ≥6.7 (with biopsy) = "Probable IIM" (≥55% probability)
    • Sensitivity: 87% / Specificity: 82% (without biopsy)
    • Sensitivity: 93% / Specificity: 88% (with biopsy)
  • Score ≥7.5 = "Definite IIM" (higher probability threshold)

Practical Application

A web-based calculator is available to compute the probability score based on patient data. 2 The criteria provide flexibility: higher probability cutoffs (≥90%) are recommended for clinical trials requiring high specificity, while lower cutoffs (≥55%) suit epidemiological studies requiring high sensitivity. 2

Critical Diagnostic Patterns

Concurrent heliotrope rash and Gottron papules have a 91% positive predictive value for pure dermatomyositis. 3 The presence of V-sign and/or shawl sign has a 100% positive predictive value for pure dermatomyositis. 3

Anti-Mi-2, anti-MJ, and anti-p155 autoantibodies are restricted to pure dermatomyositis (100% positive predictive value when present). 3

Performance and Validation

External validation demonstrated 100% sensitivity with no misclassification when sufficient data were available. 2 In the UK/Ireland Juvenile Dermatomyositis register, 92% of 332 cases could be classified with 100% sensitivity using the 55% probability cutoff. 2

The cross-validated area under the curve was 0.933 without biopsy and 0.942 with biopsy. 2

Important Caveats

Perifascicular atrophy is not specific for dermatomyositis—it occurs equally in overlap myositis with dermatomyositis features (30%) and pure dermatomyositis (17%). 3 The absolute specificity of the DM rash and perifascicular atrophy for pure dermatomyositis has been lost with modern understanding of overlap syndromes. 3

The criteria can be applied to patients with overlap diagnoses such as mixed connective tissue disease or systemic lupus erythematosus with myositis, since these patients were included among IIM cases in the derivation cohort. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Classification Criteria for Dermatomyositis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.